Brief: Milestone Pharmaceuticals Reports Third Quarter Financial Results

Milestone Pharmaceuticals

10/11/2022 13:04

Nov 10 (Reuters) - Milestone Pharmaceuticals Inc
 MIST.O :
    * MILESTONE PHARMACEUTICALS REPORTS THIRD QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATE
    * COMPANY PLANS TO SUBMIT NDA FOR ETRIPAMIL IN PSVT TO U.S.
FDA IN
MID-2023 PENDING AGENCY FEEDBACK
    * PHASE 3 RAPID TRIAL OF ETRIPAMIL IN PATIENTS WITH PSVT
ACHIEVED
PRIMARY EFFICACY ENDPOINT
    * EXPECT CURRENT CASH, CASH EQUIVALENTS, AND SHORT-TERM
INVESTMENTS TO FUND OPERATIONS THROUGH 2023
    * AS OF SEPTEMBER 30, 2022, MILESTONE HAD CASH, CASH
EQUIVALENTS,
AND SHORT-TERM INVESTMENTS OF $77.2 MILLION
    * QTRLY LOSS PER SHARE $0.34
    * Q3 EARNINGS PER SHARE VIEW $-0.41 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nCNWw0V0ra 
Further company coverage:  MIST.O 
 ((Reuters.Briefs@thomsonreuters.com;))